Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
Date:5/17/2010

INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 – 8, 2010, during which the company will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine HCl for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck-Serono.  

Of note are two Phase II ALIMTA studies (ASCO Abstracts #7082 and #7087), which both evaluate ALIMTA plus platinum-based chemotherapy in combination with concurrent radiation therapy in patients with advanced non-small cell lung cancer (NSCLC).  Several studies evaluating GEMZAR in combination with other potential therapies are also slated for presentation at the meeting.  

"Lilly Oncology research teams around the world are committed to finding new ways to improve and prolong the lives of people living with cancer," said John H. Johnson, president of Lilly Oncology.  "We are constantly studying new uses for our established therapies and discovering new molecules – all in the hopes of changing the way we treat cancer."  

In addition to studies on marketed Lilly Oncology products, new data will also be presented at ASCO on several Lilly Oncology molecules in clinical development, namely tasisulam (an anti-cancer agent), and ImClone's ramucirumab and cixutumumab (both are IgG1 monoclonal antibodies).  

Studies of note for ALIMTA include:

  • Abstract #7082: General Poster Session: '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... What do Saturn and flowers have in common? , ... recognizable in the natural world. Now, at an extremely ... of Massachusetts have created a unique set of conditions ... consistently assemble themselves into these and other complex shapes. ...
... (Nasdaq: FOLD ) announced today that Stephen ... resigned from the Company,s Board of Directors effective February ... of Amicus, board since 2004. About Amicus Therapeutics ... novel, oral therapeutics known as pharmacological chaperones for the ...
... Directors wishes to confirm to Stockholders that at its meeting ... 15 with effect from February 17, 2009. This initiative ... interests of keeping stockholders and other stakeholders informed the Board ... release the company from its United States Securities and Exchange ...
Cached Biology Technology:Sophisticated nano-structures assembled with magnets 2Sophisticated nano-structures assembled with magnets 3EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
(Date:9/18/2014)... GSA Bulletin study uses tree rings to document ... Wash in northern New Mexico, USA. By determining burial ... investigators were able to precisely date arroyo sedimentary beds ... data with aerial imagery, LiDAR, longitudinal profiles, and repeat ... Arroyos are deep, oversized channels that have vertical or ...
(Date:9/18/2014)... September 18, 2014 New research into the Crimean-Congo ... a severe hemorrhagic disease in humans similar to that ... for CCHFV infection. This discovery has the potential to ... pathogen. , The research, reported in a ... and conducted by scientists at the Texas Biomedical ...
(Date:9/18/2014)... Station ever starts a "frequent flyers" program, fruit flies ... orbiting laboratory has hosted increasing numbers of fruit fly ... space station in April, and another is scheduled launch ... planned to launch in December. , Fruit flies are ... and in space. Model organisms can reveal the basis ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... Sochi Winter Olympics including the biathlon shooting events, now is ... the use of lead shot to prevent wildlife poisoning and ... co-authored this month by a University of Guelph biologist. ... training by Olympic shooters pose a threat to birds and ...
... Plastic shopping bags, an abundant source of litter ... diesel, natural gas and other useful petroleum products, researchers ... it requires and results in transportation fuels diesel, ... ultra-low-sulfur diesels and biodiesels. Other products, such as natural ...
... know that a scarred heart cannot beat the way it ... the physical heart, at least. A team of University ... tissue into colonies of beating heart cells. Their findings could ... a heart attack. Previous work in direct reprogramming, jumping ...
Cached Biology News:Study: IOC should ban lead shot to help wildlife, water 2Plastic shopping bags make a fine diesel fuel, researchers report 2Help for a scarred heart: Scarring cells turned to beating muscle 2
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
7G10 anti-Fasciclin III...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
Biology Products: